Matteo Fiorenti

Venous thromboembolism reporting in fusion-positive NSCLC treated with tyrosine kinase inhibitors: A systematic review of safety reporting and protocol-level provisions in phase I-IV clinical trials

BACKGROUND: Venous thromboembolism (VTE) is increasingly recognized as a clinically relevant complication in patients with fusion-positive non-small cell lung cancer (NSCLC). However, the completeness and consistency of thromboembolic safety reporting in clinical trials of tyrosi...